In recent trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 0.93 million shares changing hands at last check today with its beta currently measuring 0.60. Company’s recent per share price level of $0.90 trading at $0.08 or 10.46% at last check today assigns it a market valuation of $166.14M. That most recent trading price of NKTR’s stock is at a discount of -114.44% from its 52-week high price of $1.93 and is indicating a premium of 27.78% from its 52-week low price of $0.65. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.32 million shares which gives us an average trading volume of 2.01 million if we extend that period to 3-months.

For Nektar Therapeutics (NKTR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.18 in the current quarter.

Nektar Therapeutics (NASDAQ:NKTR) trade information

Upright in the green today for gaining 10.46%, in the last five days NKTR remained trading in the green while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $0.90 price level, adding 5.26% to its value on the day. Nektar Therapeutics’s shares saw a change of -3.15% in year-to-date performance and have moved 2.59% in past 5-day. Nektar Therapeutics (NASDAQ:NKTR) showed a performance of 23.21% in past 30-days. Number of shares sold short was 6.62 million shares which calculate 2.26 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 18.5 to the stock, which implies a rise of 95.14% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -566.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -566.67% for stock’s current value.

Nektar Therapeutics (NKTR) estimates and forecasts

This year revenue growth is estimated to fall -36.41% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.72M for the same. And 8 analysts are in estimates of company making revenue of 13.6M in the next quarter. Company posted 21.64M and 23.49M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.49% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -8.97% while estimates for its earnings growth in next 5 years are of -11.91%.

Nektar Therapeutics (NASDAQ:NKTR)’s Major holders

Insiders are in possession of 1.27% of company’s total shares while institution are holding 72.51 percent of that, with stock having share float percentage of 73.45%. Investors also watch the number of corporate investors in a company very closely, which is 72.51% institutions for Nektar Therapeutics that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at NKTR for having 17.88 million shares of worth $22.17 million. And as of 2024-06-30, it was holding 8.5599 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 15.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7823 of outstanding shares, having a total worth of $18.79 million.

On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 6.65 shares of worth $5.97 million or 3.61% of the total outstanding shares. The later fund manager was in possession of 5.72 shares on Dec 31, 2024, making its stake of worth around $5.14 million in the company or a holder of 3.10% of company’s stock.